| pubmed-article:3007161 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0030567 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0005821 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0034783 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C2004454 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0237753 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C0205216 | lld:lifeskim |
| pubmed-article:3007161 | lifeskim:mentions | umls-concept:C1979845 | lld:lifeskim |
| pubmed-article:3007161 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:3007161 | pubmed:dateCreated | 1986-4-29 | lld:pubmed |
| pubmed-article:3007161 | pubmed:abstractText | [3H]-yohimbine binding sites were quantified in platelets from Parkinsonians with no clinical signs of dysautonomia. Never-treated Parkinsonians had a lower specific binding than control subjects. This alteration was associated with decreased epinephrine-induced platelet aggregation. Treatment with dopaminergic agents induced a significant increment of [3H]-yohimbine binding sites. These results show that Parkinson's disease is associated with a reduced number of peripheral alpha 2 adrenoceptors and that dopaminergic agents induce partial recovery. | lld:pubmed |
| pubmed-article:3007161 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3007161 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3007161 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3007161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3007161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3007161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3007161 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3007161 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3007161 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:3007161 | pubmed:issn | 0014-2972 | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:BerlanMM | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:LafontanMM | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:MontastrucJ... | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:VilleneuveAA | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:BonevAA | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:RascolAA | lld:pubmed |
| pubmed-article:3007161 | pubmed:author | pubmed-author:CaranobeCC | lld:pubmed |
| pubmed-article:3007161 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3007161 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:3007161 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3007161 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3007161 | pubmed:pagination | 403-7 | lld:pubmed |
| pubmed-article:3007161 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:meshHeading | pubmed-meshheading:3007161-... | lld:pubmed |
| pubmed-article:3007161 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3007161 | pubmed:articleTitle | Platelet alpha 2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatment. | lld:pubmed |
| pubmed-article:3007161 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3007161 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3007161 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3007161 | lld:pubmed |
